- Home
- DAWN vs RZLT Comparison
DAWN vs RZLT Comparison
Compare DAWN & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- RZLT
- Stock Information
- Founded
- DAWN 2018
- RZLT 2010
- Country
- DAWN United States
- RZLT United States
- Employees
- DAWN N/A
- RZLT N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- RZLT Health Care
- Exchange
- DAWN Nasdaq
- RZLT Nasdaq
- Market Cap
- DAWN 624.8M
- RZLT 626.4M
- IPO Year
- DAWN 2021
- RZLT N/A
- Fundamental
- Price
- DAWN $7.19
- RZLT $7.81
- Analyst Decision
- DAWN Strong Buy
- RZLT Strong Buy
- Analyst Count
- DAWN 7
- RZLT 5
- Target Price
- DAWN $27.86
- RZLT $12.50
- AVG Volume (30 Days)
- DAWN 1.1M
- RZLT 842.7K
- Earning Date
- DAWN 10-29-2025
- RZLT 11-06-2025
- Dividend Yield
- DAWN N/A
- RZLT N/A
- EPS Growth
- DAWN N/A
- RZLT N/A
- EPS
- DAWN N/A
- RZLT N/A
- Revenue
- DAWN $187,638,000.00
- RZLT N/A
- Revenue This Year
- DAWN $12.56
- RZLT N/A
- Revenue Next Year
- DAWN $48.02
- RZLT N/A
- P/E Ratio
- DAWN N/A
- RZLT N/A
- Revenue Growth
- DAWN 2190.50
- RZLT N/A
- 52 Week Low
- DAWN $5.64
- RZLT $2.22
- 52 Week High
- DAWN $16.76
- RZLT $8.34
- Technical
- Relative Strength Index (RSI)
- DAWN 52.01
- RZLT 72.08
- Support Level
- DAWN $7.18
- RZLT $6.92
- Resistance Level
- DAWN $7.58
- RZLT $8.34
- Average True Range (ATR)
- DAWN 0.27
- RZLT 0.31
- MACD
- DAWN -0.03
- RZLT 0.02
- Stochastic Oscillator
- DAWN 33.92
- RZLT 64.31
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.